Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACHVNASDAQ:AKEROTCMKTS:BGMDOTCMKTS:FPMIOTCMKTS:RGDXQ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHVAchieve Life Sciences$2.20-2.7%$3.02$1.84▼$5.31$75.61M1.51260,385 shs817,661 shsAKERAkers Biosciences$0.12+2.1%$3.56$1.65▼$6.97$1.97M0.3769,876 shs3.41 million shsBGMDBG Medicine$0.00$0.00▼$0.00N/A2.52250 shsN/AFPMIFluoroPharma Medical$0.00$0.00▼$0.00N/AN/A100 shsN/ARGDXQResponse Genetics$0.00$0.00▼$0.00N/AN/AN/AN/A7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHVAchieve Life Sciences0.00%-1.35%-42.56%+0.92%-51.22%AKERAkers Biosciences+2.07%-5.82%-29.56%-70.75%-93.43%BGMDBG Medicine0.00%0.00%0.00%0.00%0.00%FPMIFluoroPharma Medical0.00%0.00%0.00%0.00%0.00%RGDXQResponse Genetics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACHVAchieve Life Sciences1.6258 of 5 stars3.80.00.00.02.30.00.6AKERAkers BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ABGMDBG MedicineN/AN/AN/AN/AN/AN/AN/AN/AFPMIFluoroPharma MedicalN/AN/AN/AN/AN/AN/AN/AN/ARGDXQResponse GeneticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACHVAchieve Life Sciences 3.50Strong Buy$14.33551.52% UpsideAKERAkers Biosciences 0.00N/AN/AN/ABGMDBG Medicine 0.00N/AN/AN/AFPMIFluoroPharma Medical 0.00N/AN/AN/ARGDXQResponse Genetics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACHVAchieve Life SciencesN/AN/AN/AN/A$0.61 per shareN/AAKERAkers Biosciences$1.58M1.25N/AN/A$5.38 per share0.02BGMDBG MedicineN/AN/AN/AN/AN/AN/AFPMIFluoroPharma MedicalN/AN/AN/AN/AN/AN/ARGDXQResponse GeneticsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACHVAchieve Life Sciences-$39.83M-$1.34N/AN/AN/AN/A-176.11%-103.32%8/12/2025 (Estimated)AKERAkers Biosciences-$3.89MN/A0.00∞N/AN/A-87.42%-73.31%N/ABGMDBG MedicineN/AN/A0.00N/AN/AN/AN/AN/AN/AFPMIFluoroPharma MedicalN/AN/A0.00N/AN/AN/AN/AN/AN/ARGDXQResponse GeneticsN/AN/A0.00N/AN/AN/AN/AN/AN/ALatest BGMD, FPMI, RGDXQ, AKER, and ACHV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ACHVAchieve Life Sciences-$0.37-$0.37N/A-$0.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACHVAchieve Life SciencesN/AN/AN/AN/AN/AAKERAkers BiosciencesN/AN/AN/AN/AN/ABGMDBG MedicineN/AN/AN/AN/AN/AFPMIFluoroPharma MedicalN/AN/AN/AN/AN/ARGDXQResponse GeneticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACHVAchieve Life Sciences0.853.513.51AKERAkers BiosciencesN/A9.229.22BGMDBG MedicineN/AN/AN/AFPMIFluoroPharma MedicalN/AN/AN/ARGDXQResponse GeneticsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACHVAchieve Life Sciences33.52%AKERAkers Biosciences5.52%BGMDBG MedicineN/AFPMIFluoroPharma MedicalN/ARGDXQResponse GeneticsN/AInsider OwnershipCompanyInsider OwnershipACHVAchieve Life Sciences3.00%AKERAkers Biosciences0.29%BGMDBG Medicine6.50%FPMIFluoroPharma Medical36.90%RGDXQResponse Genetics4.85%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACHVAchieve Life Sciences2034.69 million33.64 millionOptionableAKERAkers Biosciences416.65 millionN/ANot OptionableBGMDBG Medicine5N/AN/ANot OptionableFPMIFluoroPharma Medical4N/AN/ANot OptionableRGDXQResponse Genetics100N/AN/ANot OptionableBGMD, FPMI, RGDXQ, AKER, and ACHV HeadlinesRecent News About These CompaniesRGDXQ Response Genetics, Inc - Seeking AlphaJuly 2 at 12:43 AM | seekingalpha.comNew framework enhances genetic prediction of drug response and side effectsDecember 5, 2024 | msn.comGenetic variation enhances cancer drug sensitivity in specific patient groups, study showsNovember 14, 2024 | msn.comRefugee response plansNovember 14, 2024 | unhcr.orgUDrug Combination Prompts Immune Response in Some Resistant Pancreatic CancersNovember 14, 2024 | msn.comNew cancer therapy strategy targets GLUT3 in regulatory T cells to supercharge anti-tumor immunityNovember 13, 2024 | msn.comCombining gene expression signature with liquid biopsy may improve response prediction to immunotherapyNovember 8, 2024 | medicalxpress.comMRGI to build a second West Circle commercial complexNovember 6, 2024 | finance.yahoo.comEpigenetic silencing of a DNA damage repair gene reveals a potential marker for pancreatic cancer treatmentNovember 6, 2024 | msn.comPrecision exercise medicine: understanding exercise response variabilityNovember 6, 2024 | bjsm.bmj.comBA 36-gene predictive score of anti-cancer drug resistance anticipates cancer therapy outcomesNovember 6, 2024 | uab.eduUWrightbus expands refurbishment division with acquisition of GB firm RGINovember 6, 2024 | msn.comBetween night and day: Research uncovers genetic basis for flies' circadian plasticityNovember 1, 2024 | msn.comRGI Airport increases security after receiving bomb threats in three aircraftsOctober 30, 2024 | telanganatoday.comTStudy uncovers six cancer susceptibility genesOctober 29, 2024 | msn.comIndigo Airlines Flights Alerted Amid Security Concerns at RGIOctober 28, 2024 | deccanchronicle.comDGenetic Variants and Escitalopram Response in MDDOctober 22, 2024 | physiciansweekly.comPHaryana Guv Dattratreya’s convoy collides at RGI airport, no injuries reportedOctober 20, 2024 | telanganatoday.comTA faster, more affordable technique for deciphering the genetics of diseaseOctober 19, 2024 | msn.comSurprise finding reveals the dual role of key neurodevelopmental gene FOXG1October 18, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIs D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker?By Nathan Reiff | June 16, 2025View Is D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker?The Other AI Chipmaker: Why Marvell's Dip Is a BuyBy Jeffrey Neal Johnson | June 12, 2025View The Other AI Chipmaker: Why Marvell's Dip Is a BuyCoinbase Stock Pops as Senate Passes GENIUS Stablecoin BillBy Leo Miller | June 19, 2025View Coinbase Stock Pops as Senate Passes GENIUS Stablecoin BillWall Street Sees More Upside for Dell and HPEBy Leo Miller | June 12, 2025View Wall Street Sees More Upside for Dell and HPEBGMD, FPMI, RGDXQ, AKER, and ACHV Company DescriptionsAchieve Life Sciences NASDAQ:ACHV$2.20 -0.06 (-2.65%) Closing price 07/3/2025 03:53 PM EasternExtended Trading$2.15 -0.05 (-2.05%) As of 07/3/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.Akers Biosciences NASDAQ:AKERAkers Biosciences, Inc. focuses on the development of a vaccine candidate against SARS-CoV-2, a coronavirus causing a pandemic. It has a collaboration agreement with Premas Biotech PVT Ltd. The company was incorporated in 1989 and is headquartered in New York, New York.BG Medicine OTCMKTS:BGMDBG Medicine, Inc. engages in the development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. It has license, development, and commercialization agreements with Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. for the automated instrument versions of galectin-3 test; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.FluoroPharma Medical OTCMKTS:FPMIFluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States. Its product candidates include BFPET, an imaging agent that has completed a Phase I clinical trial in stress-testing for patients with presumptive or proven coronary artery disease (CAD); and CardioPET, a molecular imaging agent, which is in Phase IIa clinical trial to assess myocardial blood flow and metabolism in patients with CAD. The company has license agreements with Massachusetts General Hospital and Sinotau USA; and clinical research agreements with Pharmaceutical Product Development, LLC, as well as Cardiovascular Imaging Technologies. FluoroPharma Medical, Inc. was founded in 2003 and is headquartered in Montclair, New Jersey.Response Genetics OTCMKTS:RGDXQResponse Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. The company offers tests for measuring predictive factors for therapy response in tumor tissue samples. It provides testing services for non-small cell lung cancer, colorectal cancer, gastric and gastroesophageal cancer, melanoma and thyroid cancer, breast cancer, and glioma through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, ResponseDX: Melanoma, ResponseDX: Thyroid, ResponseDX: Breast, ResponseDX: Glioma, and ResponseDX: Tissue of Origin test suites. The company also develops tests for other tumor types; and provides technical component and professional component testing services. It serves community based oncologists, pathologists, physician offices, hospitals, and pharmaceutical companies through its sales force. The company was formerly known as Bio Type, Inc. and changed its name to Response Genetics, Inc. in August 2000. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
